C
Carlos Santonja
Researcher at Autonomous University of Madrid
Publications - 92
Citations - 1612
Carlos Santonja is an academic researcher from Autonomous University of Madrid. The author has contributed to research in topics: Medicine & Lymphoma. The author has an hindex of 20, co-authored 83 publications receiving 1216 citations. Previous affiliations of Carlos Santonja include Sofia University.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases
Isabel Colmenero,Carlos Santonja,M Alonso-Riaño,Lucero Noguera-Morel,Angela Hernández-Martín,David Andina,Thomas Wiesner,José Luis Rodríguez-Peralto,Luis Requena,Antonio Torrelo +9 more
TL;DR: Chilblains (‘COVID toes’) are being seen with increasing frequency in children and young adults during the COVID‐19 pandemic, and causality of SARS‐CoV‐2 has not yet been established.
Journal ArticleDOI
Guidelines for processing and reporting of prostatic needle biopsies.
Theo H. van der Kwast,C. Lopes,Carlos Santonja,Carl-Gustaf Pihl,I. Neetens,Pekka Martikainen,S. Di Lollo,Lukas Bubendorf,Robert F. Hoedemaeker +8 more
TL;DR: The adoption of an unequivocal and uniform way of reporting lesions encountered in prostatic needle biopsies is considered helpful for decision taking by the clinician, and the definition of parameters for quality control of prostatic needles biopsy diagnostics will further facilitate clinical epidemiological multicentre studies of prostate cancer.
Journal ArticleDOI
Erythema multiforme-like lesions in children and COVID-19.
Antonio Torrelo,David Andina,Carlos Santonja,Lucero Noguera-Morel,Marta Bascuas-Arribas,Jara Gaitero-Tristán,José Antonio Alonso-Cadenas,Silvia Escalada-Pellitero,Angela Hernández-Martín,Mercedes de la Torre-Espi,Isabel Colmenero +10 more
TL;DR: The coincidence of EM, a condition commonly related to viruses, and chilblains in the setting of COVID‐19, and the positivity for SARS‐CoV/SARS‐ CoV‐2 spike protein by immunohistochemistry strongly suggest a link between EM‐like lesions and SARS-CoV‐ 2.
Journal ArticleDOI
Pleomorphic dermal sarcoma: a more aggressive neoplasm than previously estimated
Juan C. Tardío,Fernando Pinedo,José A. Aramburu,Dolores Suárez-Massa,A. Pampín,Luis Requena,Carlos Santonja +6 more
TL;DR: Pleomorphic dermal sarcoma is a rare neoplasm sharing pathological features with atypical fibroxanthoma, but adding tumor necrosis, invasion beyond superficial subcutis or vascular or perineural infiltration.
Journal ArticleDOI
Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts.
Sarah Haggenmüller,Roman C. Maron,Achim Hekler,Jochen Utikal,Catarina Barata,Raymond L. Barnhill,Helmut Beltraminelli,Carola Berking,Brigid Betz-Stablein,Andreas Blum,Stephan Alexander Braun,Richard A. Carr,Marc Combalia,María Teresa Fernández-Figueras,Gerardo Ferrara,Sylvie Fraitag,Lars E. French,Frank Friedrich Gellrich,Kamran Ghoreschi,Matthias Goebeler,Pascale Guitera,Holger A. Haenssle,Sebastian Haferkamp,Lucie Heinzerling,Markus V. Heppt,Franz J. Hilke,Sarah Hobelsberger,Dieter Krahl,Heinz Kutzner,Aimilios Lallas,Konstantinos Liopyris,Mar Llamas-Velasco,Josep Malvehy,Friedegund Meier,Cornelia S. L. Müller,Alexander A. Navarini,Cristian Navarrete-Dechent,Antonio Perasole,Gabriela Poch,Sebastian Podlipnik,Luis Requena,Veronica Rotemberg,Andrea Saggini,Omar P. Sangueza,Carlos Santonja,Dirk Schadendorf,Bastian Schilling,Max Schlaak,Justin Gabriel Schlager,M. Sergon,Wiebke Sondermann,H. Peter Soyer,Hans Starz,Wilhelm Stolz,Esmeralda Vale,Wolfgang Weyers,Alexander Zink,Eva Krieghoff-Henning,Jakob Nikolas Kather,Christof von Kalle,Daniel B. Lipka,Stefan Fröhling,Axel Hauschild,Harald Kittler,Titus J. Brinker +64 more
TL;DR: In this article, the authors systematically analyzed the current state of research on reader studies involving melanoma and assessed their potential clinical relevance by evaluating three main aspects: test set characteristics (holdout/out-of-distribution data set, composition), test setting (experimental/clinical, inclusion of metadata) and representativeness of participating clinicians.